Welcome toTherapeutics PLUS

Brought to you byAccredited by

Therapeutics plus A5 KL.qxd 29/12/08 15:51 Page 1

Therapeutics PLUS is a learning programme for healthcareprofessionals developed by Prescriber and the Medway School of

Pharmacy in association with Pfizer. This platform is aimed primarily at non-medical prescribers, but will be relevant and of value to all healthcare

professionals. The programme is designed to support their continuingprofessional development as an extension to the qualifying coursework. Each module covers an area of therapeutics and includes case studies andsuggestions for extended CPD activities.

Each module is followed by a series of multiple-choice questions, which aremarked automatically, and a certificate is provided on successful completion ofeach module. Following successful completion students can take a furtherassessment to gain Masters credits from the Medway School of Pharmacy.

The programme intends to cover a broad range of subject areas and newmodules will be rolled out over time. Modules available for study or indevelopment include:

Neuropathic PainLearning outcomes:

• To understand the definitions, causes and epidemiology of chronic pain.

• To be aware of the presentation and assessment of neuropathic pain.

• To understand the pharmacological and non-pharmacological strategiesfor treating neuropathic pain.

Smoking CessationLearning outcomes:

• To understand the harmful effects of smoking and the benefits of cessation.

• A detailed knowledge of the evidence base supporting pharmacologicaland non-pharmacological therapeutic interventions used in the holisticmanagement of smoking cessation.

Therapeutics PLUS

Therapeutics plus A5 KL.qxd 29/12/08 15:51 Page 2

t h e r a p e u t i c s

PLUS

AsthmaLearning outcomes:

• To understand the structure of the lungs and the derivation of measuresof lung function.

• To be aware of the causes of asthma and its effect on lung function.

• To be familiar with current clinical guidance on the management ofasthma and the properties of the drugs most widely prescribed, and placethis in the context of local clinical practice.

COPDLearning outcomes:

• To understand the structure of the lungs and the derivation of measuresof lung function.

• To be aware of the causes of COPD and its effect on lung function.

• To be familiar with current clinical guidance on the management of COPDand the properties of the drugs most widely prescribed, and place this inthe context of local clinical practice.

Modules to be developed in the future include:Female Urinary IncontinenceErectile Dysfunction

To register for Therapeutics PLUS:Please register online at www.therapeuticsplus.com

Further information:For further information either log on to www.therapeuticsplus.comor contact your Pfizer representative. *Please note there is no obligation to see the representative in order to receive thisinformation.

Therapeutics plus A5 KL.qxd 29/12/08 15:51 Page 3

This training has been developed by

Prescriber is the leading journal for primary care that covers therapeutics andissues around prescribing. Targeting key prescribing decision makers, thearticles published in Prescriber are accessible to a multi-disciplinaryprescribing audience. Articles are written by leading specialists and GPs, andall are peer reviewed.

In partnership with the

The Medway School of Pharmacy is a unique collaboration between theUniversity of Greenwich and the University of Kent. They offer innovativelydesigned patient focussed undergraduate and postgraduate programmes toaddress the needs of healthcare professionals. Their aim is to establish aninternationally recognised research reputation based in multidisciplinaryteamwork.

Brought to you by

As one of the world’s leading pharmaceutical companies, Pfizer is at thecutting-edge of the research and development of medicines. Medicalinnovation is at the core of their business, but Pfizer also works in partnershipwith a wide range of health professionals, organisations, and patient groups,continually searching for new ways to promote and support these people andthe work they do.

HCO409 Date of preparation Oct 2008

t h e r a p e u t i c s

PLUS

Therapeutics plus A5 KL.qxd 29/12/08 15:51 Page 4